Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have earned a consensus recommendation of “Buy” from the eight analysts that are presently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $46.6667.

Several equities analysts recently commented on AAPG shares. BTIG Research reiterated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Deutsche Bank Aktiengesellschaft started coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 price target on the stock. Finally, China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th.

Ascentage Pharma Group International Stock Down 4.8%

Shares of NASDAQ:AAPG opened at $18.56 on Tuesday. Ascentage Pharma Group International has a 12 month low of $18.56 and a 12 month high of $48.45. The firm’s 50-day moving average is $23.75 and its 200 day moving average is $26.53. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The company had revenue of $24.72 million for the quarter. As a group, sell-side analysts expect that Ascentage Pharma Group International will post -1.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several large investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Ascentage Pharma Group International in the 3rd quarter valued at about $96,000. ABC Arbitrage SA purchased a new stake in Ascentage Pharma Group International in the 3rd quarter valued at about $204,000. Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International in the 3rd quarter valued at about $383,000. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International in the 2nd quarter valued at about $391,000. Finally, UBS Group AG boosted its position in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares during the period.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.